Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus Standard of Care (SoC)
durvalumab alone
ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020
  NCT02352948
RCTmNSCLC - L2 - PDL1 positivedurvalumabstandard of care : erlotinib, gemcitabine or vinorelbinepatients with PD-L1 positive locally advanced or metastatic non small cell lung cancer who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for stage IIIB/IV locally advanced or mNSCLC;62 / 64some concern
suggested
  • suggested 37 % decrease in deaths (OS)